ASCO 2012 ... the latest in cancer research

Tecvayli responses were found to be slightly lower in patients with relapsed/refractory myeloma treated with another BCMA-targeted therapy.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

I use affirmation as a technique to turn my negative thoughts about colon cancer into positive ones. Now, I see cancer as a blessing in disguise.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

A breakthrough therapy designation was granted to petosemtamab by the FDA to treat patients with recurrent or metastatic head and neck cancers.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.